Overview
Whether you arrived from a “Injective vs OUSG” query or from PEPS coin pages, this hub aggregates ranks, performance and module-backed signals into one canonical URL.
Quick winners
Full comparison
| Metric | INJ | OUSG |
|---|---|---|
| Price | $4.99 | $1,861.70 |
| Market Cap | $490.41M | $378.35M |
| FDV | — | — |
| Volume 24h | $2.65M | $0.000000 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 112.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | OUSG |
|---|---|---|
| 1H | — | — |
| 24H | +1.03% | +0.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | OUSG |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 65.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Indicator stacks for INJ/OUSG currently lean on separate regimes: neutral versus bearish. Treat MACD and RSI as context, not as standalone entry triggers.
Fundamentals
| Metric | INJ | OUSG |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
OUSG
Pros and cons
Pros of Injective
- Higher ranking for Injective can translate into tighter spreads on major venues.
- Injective has an established coin page footprint on PEPS for continuous monitoring.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
Cons of Injective
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- When dominance narratives fade, Injective can lag hotter rotation names.
Pros of OUSG
- Diversifying versus Injective with OUSG can change portfolio factor exposure.
- Narrative optionality around OUSG can reprice quickly when catalysts appear.
- OUSG can offer higher relative beta when market attention rotates toward its niche.
Cons of OUSG
- Weaker market-cap standing may leave OUSG more exposed to liquidity droughts.
- Trend failures on OUSG often travel faster than on more established assets.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
Which looks stronger right now?
Data currently points to a probabilistic edge for Injective on size and Injective on activity. Neither reading guarantees future returns.
AI summary
For readers asking which is “better”, the honest answer is conditional. Injective and OUSG solve overlapping but not identical market jobs. On-chain and developer fields, when available, add slower-moving context beneath the tape. Missing fundamentals should be treated as unknown, not as zeros. If your thesis is long-term adoption, weight fundamentals and liquidity; if tactical, weight trend/momentum — and always define invalidation.
FAQ
Which is better, Injective or OUSG?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or OUSG?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and OUSG.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.